Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer
NCT03056833
Completed
Investigators hypothesize that concurrent ribociclib treatment and chemotherapy will enhance the response to platinum-based therapy and maintenance therapy will slow ovarian cancer tumor growth leading to prolongation in progression free survival.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/01/2022
Locations: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan +7 locations
Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma
Register for Updates
Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer
NCT02394535
Completed
This phase I trial studies the side effects and best dose of nab-paclitaxel when given together with capecitabine and radiation therapy following first treatment with chemotherapy (induction therapy) in treating patients with pancreatic cancer that is not spread to tissue far away but is not operable due to abutment or encasement of blood vessels nearby (locally advanced). Drugs used in chemotherapy, such as nab-paclitaxel and capecitabine, work in different ways to stop the growth of tumor cell... Read More
Gender:
ALL
Ages:
19 years and above
Trial Updated:
08/31/2022
Locations: M D Anderson Cancer Center, Houston, Texas +4 locations
Conditions: Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v6 and v7, Stage IIA Pancreatic Cancer AJCC v6 and v7, Stage IIB Pancreatic Cancer AJCC v6 and v7, Stage III Pancreatic Cancer AJCC v6 and v7
Register for Updates
Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies
NCT01113476
Completed
The goal of this clinical research study is to find the highest tolerable dose of the combination of Abraxane (nab-paclitaxel), Gemzar (gemcitabine), and Avastin (bevacizumab) that can be given to patients with advanced cancer. The safety of this drug combination will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/31/2022
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Cancer
Register for Updates
Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
NCT00373217
Terminated
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving vaccine therapy and chemotherapy after surgery may kill any tumor ce... Read More
Gender:
FEMALE
Ages:
Between 18 years and 120 years
Trial Updated:
08/25/2022
Locations: University of Virginia Cancer Center, Charlottesville, Virginia
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Register for Updates
A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer
NCT02370238
Completed
The Objectives of this study: The primary objective of the study was to evaluate progression-free survival (PFS) (defined as the number of days between the date of randomization and the date of clinical disease progression (PD) according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1, as assessed by Independent Radiology Review, or death for any cause, whichever occured first) in patients with metastatic triple-negative breast cancer (TNBC) treated with the combin... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/23/2022
Locations: Southern Cancer Center, Mobile, Alabama +76 locations
Conditions: Metastatic Breast Cancer
Register for Updates
Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours
NCT03894540
Terminated
The purpose of the protocol is to determine safety, tolerability, recommended dose (RD), pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of IPN60090 as a single agent (Part A) and in combination with pembrolizumab (Part B) or paclitaxel (Part C) in patients with advanced solid tumours and to evaluate food effect (Part D).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/22/2022
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Solid Tumor
Register for Updates
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
NCT04060342
Terminated
This first-in-human (FIH ) study is an open-label, multicenter study that consists of a Phase 1 Dose Escalation/Expansion phase of GB1275 monotherapy or in combination with Anti-PD-1 Antibody or in combination with Standard of Care in Patients with Metastatic Pancreatic Adenocarcinoma followed by a Phase 2 Basket Expansion phase in Patients with Specified Metastatic Solid Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/17/2022
Locations: UCSF Medical Center at Mission Bay, San Francisco, California +7 locations
Conditions: Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Microsatellite Stable Colorectal Cancer, Non-small Cell Lung Cancer, Small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma, Renal Cell Carcinoma, Hepatocellular Carcinoma
Register for Updates
A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer
NCT02967133
Terminated
The optimal prioritization of second-line chemotherapy and immune therapy based on demographic or biomarker data is an area of ongoing investigation. The hypothesis of this study is that there may be an additive or synergistic antitumor effect of combined chemotherapy and nivolumab in the second-line treatment of NSCLC as an important concept to test in a clinical trial. Previously treated NSCLC remains a setting of unmet clinical need despite recent clinical research progress. Early progression... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/16/2022
Locations: St. Elizabeth's Healthcare, Edgewood, Kentucky +3 locations
Conditions: Non-Small-Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Nonsmall Cell Lung Cancer, Non Small Cell Lung Cancer Recurrent
Register for Updates
PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients
NCT03064854
Terminated
The primary purpose of this study is to establish the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) of PDR001 when administered in combination with platinum-doublet chemotherapy and other immunooncology agent(s) in treatment naive patients with PD-L1 unselected, advanced NSCLC, and to estimate the preliminary anti-tumor activity in this patient population.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2022
Locations: Highlands Oncology Group, Fayetteville, Arkansas +22 locations
Conditions: Non-small Cell Lung Cancer
Register for Updates
LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer
NCT02328105
Completed
ABRAXANE, based on results from prior studies, is a promising drug in squamous cell carcinoma of the lung. This study will help to explore the combination of ABRAXANE and carboplatin more thoroughly in the subgroup of patients who had the best response in prior studies as well as determine whether there are any biomarkers which can predict for response.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2022
Locations: Levine Cancer Institute, Charlotte, North Carolina
Conditions: Lung Cancer
Register for Updates
Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma
NCT02798536
Completed
Background: LMB-100 is a man-made protein. It is attracted to the mesothelin protein. This is found in many tumors, including mesothelioma. But it is found in only a very small number of normal tissues. After binding to mesothelin on tumors, LMB-100 attacks and kills cancer cells. Researchers want to test LMB-100 in people with advanced mesothelioma. Objective: To find a safe dose and anti-tumor activity of LMB-100 for people with advanced mesothelioma. Eligibility: Adults ages 18 and older... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2022
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Mesothelioma
Register for Updates
Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer
NCT02227940
Completed
This phase I trial studies the side effects and best dose of ceritinib and combination chemotherapy in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or pancreatic cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or has spread to other places in the body (metastatic). Ceritinib may stop the growth of tumor cells by blocking some of the enzymes neede... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/20/2022
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Advanced Malignant Solid Neoplasm, ALK Positive, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Register for Updates